Related Experiment Video

Updated: Nov 9, 2025

A Semi-Quantitative Drug Affinity Responsive Target Stability DARTS assay for studying Rapamycin/mTOR interaction
05:28

A Semi-Quantitative Drug Affinity Responsive Target Stability DARTS assay for studying Rapamycin/mTOR interaction

Published on: August 27, 2019

17.0K

A Web of Science-based scientometric analysis about mammalian target of rapamycin signaling pathway in kidney disease

Lian-Zhong Wu1,2, Yi-Qin Weng1,2, Yi-Xin Ling1,2

  • 1Department of Hematology, The First Affiliated Hospital of Wenzhou Medical University, Wenzhou, China.

Translational Andrology and Urology
|April 14, 2021
PubMed
Abstract

Insights

Scientometric analysis of the mammalian target of rapamycin (mTOR) pathway in kidney disease reveals key research areas. Future trends focus on diabetic nephropathy, kidney transplantation, and specific genetic disorders.

Area of Science:

  • Nephrology
  • Molecular Biology
  • Biomedical Research

Background:

  • The mammalian target of rapamycin (mTOR) pathway is crucial for kidney cell metabolism, growth, and proliferation.
  • Dysregulation of the mTOR pathway is implicated in various kidney diseases.

Purpose of the Study:

  • To analyze current research focuses on the mTOR pathway in kidney disease.
  • To predict future research trends in this field using scientometric methods.

Main Methods:

  • Bibliographic data from the Web of Science Core Collection (WoSCC) were analyzed.
  • Scientometric tools including Carrot2, VOSviewer, and CiteSpace were employed.
  • Analysis covered author, institute, and country contributions, research hotspots, and trend prediction.

Main Results:

  • A total of 2,585 manuscripts on the mTOR pathway in kidney disease were identified up to July 10, 2020.
  • The United States is a leading contributor to research in this area.
  • Key research hotspots include diabetic nephropathy, kidney transplantation, autosomal dominant polycystic kidney disease, tuberous sclerosis complex, renal cell carcinoma, and autophagy.

Conclusions:

  • Diabetic nephropathy, kidney transplantation, autosomal dominant polycystic kidney disease, tuberous sclerosis complex, renal cell carcinoma, and autophagy are identified as future research hot spots.
  • Further investigation into these areas is warranted to advance understanding and treatment of kidney diseases related to the mTOR pathway.
Keywords:
BibliometricsCiteSpaceTOR serine-threonine kinasesVOSviewerkidney diseases

More Related Videos

Comparative Proteomic Analysis of Whole Kidney, Medulla, and Cortical Tubules in Diabetic Pathogenesis of Kidney Injury in Mice10:31

Comparative Proteomic Analysis of Whole Kidney, Medulla, and Cortical Tubules in Diabetic Pathogenesis of Kidney Injury in Mice

Published on: May 2, 2025

419
Quantitative Real-Time Polymerase Chain Reaction Evaluation of MicroRNA Expression in Kidney and Serum of Mice with Age-Dependent Renal Impairment06:48

Quantitative Real-Time Polymerase Chain Reaction Evaluation of MicroRNA Expression in Kidney and Serum of Mice with Age-Dependent Renal Impairment

Published on: April 29, 2022

2.5K

Related Concept Videos

mTOR Signaling and Cancer Progression03:03

mTOR Signaling and Cancer Progression

The mammalian target of rapamycin or mTOR protein was discovered in 1994 due to its direct interaction with rapamycin. The protein gets its name from a yeast homolog called TOR. The mTOR protein complex in mammalian cells plays a major role in balancing anabolic processes such as the synthesis of proteins, lipids, and nucleotides and catabolic processes, such as autophagy in response to environmental cues, such as availability of nutrients and growth factors.
The mTOR pathway or the...
4.0K
PI3K/mTOR/AKT Signaling Pathway01:22

PI3K/mTOR/AKT Signaling Pathway

The mammalian target of rapamycin  (mTOR) is a serine/threonine kinase that regulates growth, proliferation, and cell survival in response to hormones, growth factors, or nutrient availability. This kinase exists in two structurally and functionally distinct forms: mTOR complex 1  (mTORC1) and mTOR complex 2  (mTORC2). The first form (mTORC1) is composed of a rapamycin-sensitive Raptor and proline-rich Akt substrate, PRAS40. In contrast,  mTORC2 consists of a...
4.4K